EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study

Ling Chen iD, Hourui Tan, Ruixuan Geng, Yifan Li, Yingyi Wang, Taisheng Li

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.15493 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Ling Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing…. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences, Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital, the Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Our study aimed to comprehensively describe the features of peripheral blood multiple immune cell phenotypes in solid tumor patients during pretreatment and after immunotherapy, providing a more convenient approach for studying the prognosis of immunotherapy in different solid tumor patients.

Methods

We prospectively recruited patients with advanced solid tumors from Peking Union Medical College Hospital (PUMCH) between February 2023 and April 2024. Using multicolor flow cytometry, our study comprehensively observed and described the signatures of peripheral blood lymphocyte subsets including activation, proliferation, function, naïve memory, and T cell exhaustion immune cell subsets in this population of pretreatment and after immunotherapy.

Results

Our study enrolled 59 advanced solid tumor patients with immunotherapy and 59 healthy controls were matched by age and gender. The results demonstrated a marked upregulation in the expression of lymphocyte activation markers CD38 and HLA‐DR, as well as exhaustion and proliferation markers PD‐1 and Ki67, in solid tumor patients compared to healthy controls. After immune checkpoint blockade (ICB) treatment, mainly the expression of Ki67CD4+T and HLA‐DRCD38CD4+T, was significantly upregulated compared to pretreatment levels ( p = 0.017, p = 0.019, respectively). We further found that gynecological tumors with better prognoses had higher baseline activation levels of CD4+ T cells compared to other solid tumors with poorer prognoses.

Conclusion

Our study elucidated the characteristics of different lymphocyte subsets in the peripheral blood of solid tumor patients. Further research revealed changes in the phenotypes of different lymphocyte subsets after ICIs treatment, with the activated phenotype of CD4+ T cells playing a crucial role in the antitumor effect. This lays the groundwork for further exploration of prognostic biomarkers and predictive models for cancer patients with immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedPrognosisAgedAdultProspective Studies

Stichwörter der Autor:innen

immune checkpoint inhibitorslymphocyte subsetsperipheral bloodsolid tumor

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of International Medical Services, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

ORCID-Profile: Ling Chen

Förderung

  • the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
  • Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital
  • the Fundamental Research Funds for the Central Universities

Zitieren

APA

Chen, L., Tan, H., Geng, R., Li, Y., Wang, Y., & Li, T. (2025). Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15493

Vancouver

Chen L, Tan H, Geng R, Li Y, Wang Y, Li T. Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15493

BibTeX
@article{Chen2025,
  author = {Chen, Ling and Tan, Hourui and Geng, Ruixuan and Li, Yifan and Wang, Yingyi and Li, Taisheng},
  title = {Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.15493}
}
Kostenlos starten →